CD4 and FOXP3 As Predictive Markers for the Recurrence of T3/T4a Stage II Colorectal Cancer: Applying a Novel Discrete Bayes Decision Rule

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Oct 17

PMID 36253752

Authors

Yuki Nakagami

Shoichi Hazama

Nobuaki Suzuki

Shin Yoshida

Shinobu Tomochika

Hiroto Matsui

Yoshitaro Shindo

Yukio Tokumitsu

Satoshi Matsukuma

Yusaku Watanabe

Michihisa Iida

Ryouichi Tsunedomi

Shigeru Takeda

Tomonobu Fujita

Yutaka Kawakami

Hiroyuki Ogihara

Yoshihiko Hamamoto

Tatsuya Ioka

Tsuyoshi Tanabe

Tomio Ueno

Hiroaki Nagano

Affiliations

Soon will be listed here.

Abstract

Background: We recently reported the relapse-free survival (RFS) significance of the combination of CD4 and forkhead box P3 (FOXP3) T-cell densities identified by immunohistochemistry in patients with stage I, II, and III colorectal cancer (CRC) who underwent curative resections. This study was designed to determine the optimal combination of markers that predict recurrence in patients with T factors of T3/T4a stage II CRC by applying a novel Bayes decision rule.

Methods: Using 137 cancer tissue specimens from T3/T4a stage II patients, 12 clinicopathologic and immune factors were analysed as predictive candidates for recurrence.

Results: Our study showed that the combination of low CD4 and low FOXP3 T-cell densities resulted in extremely poor RFS.

Conclusions: Adjuvant chemotherapy may be considered for patients with a combination of low CD4 and low FOXP3 T-cell densities. The discovery of this new prognostic indicator is important for the appropriate management of patients undergoing curative resection for T3/T4a stage II CRC.

Citing Articles

The Impact of Nutritional Status and Tumor-Infiltrating Lymphocytes (CD4+ and CD8+) on Chemotherapy Response in Colorectal Cancer Patients.

Lukman K, Septianto R, Rudiman R, Ruchimat T, Sribudiani Y, Nugraha P Cancer Manag Res. 2025; 17:197-209.

PMID: 39906521 PMC: 11792878. DOI: 10.2147/CMAR.S503985.

Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer.

Yuan H, Gui R, Wang Z, Fang F, Zhao H Front Immunol. 2023; 14:1128774.

PMID: 36798129 PMC: 9927011. DOI: 10.3389/fimmu.2023.1128774.

References

You K, Park H, Park S, Sohn D, Oh J, Lee D . Laparoscopic approach for T4 colon cancer can be associated with poor prognosis in right-sided T4b tumours. Eur J Surg Oncol. 2021; 47(7):1645-1650. DOI: 10.1016/j.ejso.2021.01.009. View

Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6(4):345-52. DOI: 10.1038/ni1178. View

Kinoshita T, Muramatsu R, Fujita T, Nagumo H, Sakurai T, Noji S . Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 2016; 27(11):2117-2123. DOI: 10.1093/annonc/mdw319. View

Sakaguchi S, Miyara M, Costantino C, Hafler D . FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010; 10(7):490-500. DOI: 10.1038/nri2785. View

Huang Y, Liao H, Zhang Y, Yuan R, Wang F, Gao Y . Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS One. 2014; 9(5):e94376. PMC: 4020764. DOI: 10.1371/journal.pone.0094376. View

. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995; 345(8955):939-44. View

Labianca R, Nordlinger B, Beretta G, Mosconi S, Mandala M, Cervantes A . Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi64-72. DOI: 10.1093/annonc/mdt354. View

Bromwich E, McArdle P, Canna K, McMillan D, McNicol A, Brown M . The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer. 2003; 89(10):1906-8. PMC: 2394435. DOI: 10.1038/sj.bjc.6601400. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Ogihara H, Iizuka N, Hamamoto Y . Prediction of Early Recurrence of Liver Cancer by a Novel Discrete Bayes Decision Rule for Personalized Medicine. Biomed Res Int. 2016; 2016:8567479. PMC: 5075355. DOI: 10.1155/2016/8567479. View

11.

Haller D, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29(11):1465-71. DOI: 10.1200/JCO.2010.33.6297. View

12.

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

13.

Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y . A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018; 96:54-63. DOI: 10.1016/j.ejca.2018.03.009. View

14.

Jain A, Dubes R, Chen C . Bootstrap techniques for error estimation. IEEE Trans Pattern Anal Mach Intell. 2011; 9(5):628-33. DOI: 10.1109/tpami.1987.4767957. View

15.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

16.

Sinicrope F, Rego R, Ansell S, Knutson K, Foster N, Sargent D . Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009; 137(4):1270-9. PMC: 2873775. DOI: 10.1053/j.gastro.2009.06.053. View

17.

Dienstmann R, Salazar R, Tabernero J . Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015; 33(16):1787-96. DOI: 10.1200/JCO.2014.60.0213. View

18.

Figueredo A, Charette M, Maroun J, Brouwers M, Zuraw L . Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004; 22(16):3395-407. DOI: 10.1200/JCO.2004.03.087. View

19.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View

20.

Rottoli M, Stocchi L, Dietz D . T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol. 2012; 19(8):2500-5. DOI: 10.1245/s10434-012-2292-8. View